Nektar Therapeutics
NKTR
138 hedge funds and large institutions have $183M invested in Nektar Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 37 increasing their positions, 34 reducing their positions, and 17 closing their positions.
691% more call options, than puts
Call options by funds: $182K | Put options by funds: $23K
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
9% more capital invested
Capital invested by funds: $168M → $183M (+$15M)
4% more funds holding
Funds holding: 133 → 138 (+5)
9% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 34
0.19% more ownership
Funds ownership: 4.91% → 5.1% (+0.19%)
Top Buyers
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.38M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.73M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$1.41M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.21M |
| 5 |
BlackRock
New York
|
+$1.03M |
Top Sellers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.48M |
| 2 |
Morgan Stanley
New York
|
-$923K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$911K |
| 4 |
Two Sigma Investments
New York
|
-$567K |
| 5 |
Two Sigma Advisers
New York
|
-$426K |
NKTR Hedge Fund Activity: Q3 2024 in Review
138 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2024, worth a combined $183M — up 8.9% from $168M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NKTR positions and 17 closed out — a net gain of 5 holders — while 37 added to existing stakes and 34 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $2.38M. The largest seller was Deep Track Capital, cutting an estimated $2.48M.
- 138 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2024, up from 133 in Q2 2024.
- Funds reported $183M of Nektar Therapeutics stock for Q3 2024, up 8.9% quarter-over-quarter.
- 22 funds opened new Nektar Therapeutics positions in Q3 2024 and 17 closed out, a net change of +5 holders.
- The largest Nektar Therapeutics buyer in Q3 2024 was Eventide Asset Management, an estimated $2.38M added.
- The largest Nektar Therapeutics seller in Q3 2024 was Deep Track Capital, an estimated $2.48M sold.
Based on aggregated 13F filings for Q3 2024.